Scarica l'app Stockscreener
175.99
0.23%
-0.41
Dopo l'orario di chiusura:
174.45
-1.54
-0.88%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BIIB Giù?
Forum
Previsione
Frazionamento azionario
Biogen Inc Borsa (BIIB) Ultime notizie
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
Biogen Inc. $BIIB Stock Position Increased by Cwm LLC - MarketBeat
Biotech pioneer who helped launch Biogen dies at 94 - The Business Journals
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge (NASDAQ:BIIB) - Seeking Alpha
Dementia Drugs Market 2025 Outlook: In-Depth Insights, - openPR.com
Ethic Inc. Boosts Stake in Biogen Inc. $BIIB - MarketBeat
Spinal Muscular Atrophy Market is expected to reach US$ 20.06 - openPR.com
Recombinant Therapeutic Antibodies And Proteins Market - openPR.com
J. L. Bainbridge & Co. Inc. Cuts Holdings in Biogen Inc. $BIIB - MarketBeat
Vontobel Holding Ltd. Sells 18,760 Shares of Biogen Inc. $BIIB - MarketBeat
Pacer Advisors Inc. Acquires 131,258 Shares of Biogen Inc. $BIIB - MarketBeat
Cns Specific Antisense Oligonucleotide MarketForecast - openPR.com
Swedbank AB Grows Stake in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc Gaining or Losing Market Support?Biogen (NASDAQ:BIIB) - Benzinga
Voya Investment Management LLC Has $8.87 Million Holdings in Biogen Inc. $BIIB - MarketBeat
Biogen to Microsoft: 4 Stocks Morningstar Likes for 2026 - TipRanks
Biogen’s Qalsody posts long-term signal in rare genetic ALS - The Pharma Letter
JAMA Neurology Data Shows Meaningful Effects With Biogen's QALSODY In Long-Term Results - Nasdaq
Macro Review: How Biogen Inc stock performs in high volatility marketsJuly 2025 Weekly Recap & Daily Oversold Bounce Ideas - moha.gov.vn
Biogen (BIIB): Reassessing Valuation After New QALSODY Data, Pipeline Progress and Renewed Growth Optimism - simplywall.st
The Bull Case For Biogen (BIIB) Could Change Following New QALSODY ALS Data And Nasdaq-100 ExitLearn Why - Yahoo Finance
Biogen (BIIB) Stock News Today (Dec. 22, 2025): QALSODY Data, Nasdaq-100 Exit, and Analyst Forecasts - ts2.tech
Biogen : Issues Statement in Response to the Passing of Charles Weissmann, MD, Ph.D., Co-Founder of Biogen - marketscreener.com
Biogen (BIIB) Phase 3 Study Highlights Benefits of QALSODY in ALS Treatment - GuruFocus
Biogen’s QALSODY shows sustained benefits for SOD1-ALS patients - Investing.com India
Biogen's QALSODY Shows Promising Long-Term Effects on Function and Survival in SOD1-ALS, Published in JAMA Neurology - Quiver Quantitative
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS - Biogen
Factor VIII deficiency treatment Market See Incredible Growth 2025-2032 | Baxter, Biogen, Inc., Bayer AG - openPR.com
Therapeutics Stocks Q3 In Review: Biogen (NASDAQ:BIIB) Vs Peers - Barchart.com
Biogen Stock Forecast for the Week Ahead (Dec. 22–26, 2025): BIIB Near 52-Week High as Leqembi Momentum Meets an Analyst Split - ts2.tech
Wedge Capital Management L L P NC Invests $27.02 Million in Biogen Inc. $BIIB - MarketBeat
Fluent Financial LLC Makes New Investment in Biogen Inc. $BIIB - MarketBeat
Biogen Stock (NASDAQ: BIIB) News and Forecasts for Dec. 20, 2025: RBC’s $210 Target, Leqembi Catalysts, and What Investors Are Watching - ts2.tech
RBC’s Confidence in Leqembi and MS Pipeline Might Change The Case For Investing In Biogen (BIIB) - simplywall.st
Biogen (BIIB) Stock Trades Up, Here Is Why - The Globe and Mail
Biogen Stock (BIIB) After-Hours on Dec. 19, 2025: Why Shares Jumped, Where They Closed After the Bell, and What to Watch Before the Next Market Open - ts2.tech
Is Biogen Inc. stock a bargain at current levelsJuly 2025 Price Swings & Safe Capital Investment Plans - ulpravda.ru
Biogen (NASDAQ:BIIB) Price Target Raised to $165.00 - MarketBeat
Why Biogen Inc. stock remains undervaluedInsider Buying & Daily Stock Momentum Reports - ulpravda.ru
Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth - Pharma Voice
Biogen Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Biogen stock rated Outperform by RBC Capital with $210 price target - Investing.com Canada
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration - GuruFocus
What margin trends mean for Biogen Inc. stockMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
BMO Capital Adjusts Price Target on Biogen to $165 From $150, Maintains Market Perform Rating - marketscreener.com
Will Biogen Inc. stock outperform international peersJuly 2025 Intraday Action & Safe Entry Trade Reports - Улправда
Biogen (BIIB): Reassessing Valuation After a Recent 3-Month Share Price Rebound - Yahoo Finance
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress - Insider Monkey
Is Biogen a Mispriced Opportunity After Renewed Interest in Its Neurology Pipeline? - simplywall.st
Will Biogen Inc. stock benefit from sector rotation2025 Macro Impact & Verified Trade Idea Suggestions - Bollywood Helpline
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Disease Trial - marketscreener.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List - TradingView — Track All Markets
Pitcairn Co. Acquires Shares of 7,454 Biogen Inc. $BIIB - MarketBeat
Biogen (BIIB) Valuation Check After Positive Neurology Data for Lecanemab and Zorevunersen - simplywall.st
Biogen Inc. (NASDAQ:BIIB) Doing What It Can To Lift Shares - 富途牛牛
Biogen’s New Study on BIIB145: A Potential Game-Changer for MS Treatment? - TipRanks
Alzheimer’s Disease Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Biogen, Eisai, Eli Lilly and Company, AB Science, Alzheon, Inc., Cerecin, BioVie, Eisai Inc - Barchart.com
Biogen Doubles Down On Immunology As Lupus Programs Near Readouts - Citeline News & Insights
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):